Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | beta-site APP-cleaving enzyme 1 | Starlite/ChEMBL | References |
Homo sapiens | cathepsin D | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | plasmepsin X | cathepsin D | 412 aa | 339 aa | 28.9 % |
Plasmodium falciparum | plasmepsin VII | beta-site APP-cleaving enzyme 1 | 401 aa | 352 aa | 21.3 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | family A2 unassigned peptidase (A02 family) | 0.2788 | 0.1708 | 0.1708 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1968 | 0.1166 | 0.4001 |
Echinococcus granulosus | 6 phosphofructo 2 kinase:fructose 2 | 0.4613 | 0.2914 | 1 |
Brugia malayi | prolyl 4-hydroxylase | 0.0205 | 0 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1968 | 0.1166 | 0.4001 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.4535 | 0.2862 | 0.9823 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1968 | 0.1166 | 0.4001 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.4535 | 0.2862 | 0.9823 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.4613 | 0.2914 | 1 |
Schistosoma mansoni | memapsin-2 (A01 family) | 0.0535 | 0.0218 | 0.0218 |
Toxoplasma gondii | oxidoreductase, 2OG-Fe(II) oxygenase family protein | 0.5566 | 0.3543 | 1 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.2723 | 0.1664 | 0.5 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.2723 | 0.1664 | 0.5 |
Schistosoma mansoni | 6-phosphofructokinase | 0.4613 | 0.2914 | 0.2914 |
Loa Loa (eye worm) | hypothetical protein | 0.4613 | 0.2914 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.4613 | 0.2914 | 1 |
Giardia lamblia | Hypothetical protein | 0.2723 | 0.1664 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.2723 | 0.1664 | 0.5 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.4613 | 0.2914 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.4535 | 0.2862 | 0.9823 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-1-like protein | 0.1968 | 0.1166 | 0.4001 |
Giardia lamblia | Hypothetical protein | 0.2723 | 0.1664 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.2645 | 0.1613 | 0.5535 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.4613 | 0.2914 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.4535 | 0.2862 | 0.9823 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.4613 | 0.2914 | 1 |
Onchocerca volvulus | 0.4613 | 0.2914 | 1 | |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.4535 | 0.2862 | 0.9823 |
Loa Loa (eye worm) | hypothetical protein | 0.1134 | 0.0614 | 0.2109 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 5 nM | Inhibition of cathepsin-D (unknown origin) using C-terminal biotinylated peptide substrate treated 30 mins before addition of peptide substrate measured after 110 mins by fluorescence polarization assay | ChEMBL. | 23856050 |
IC50 (binding) | = 9 nM | Inhibition of recombinant BACE-1 (unknown origin) expressed in Escherichia coli using biotinylated peptide substrate treated 20 mins before substrate addition measured after 3 hrs by fluorescence polarization assay | ChEMBL. | 23856050 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.